Guardant Health (NASDAQ:GH) Upgraded to Strong-Buy at Mizuho

Mizuho upgraded shares of Guardant Health (NASDAQ:GH) to a strong-buy rating in a research report sent to investors on Wednesday morning,Zacks.com reports.

A number of other equities analysts have also commented on the company. JPMorgan Chase & Co. lifted their price objective on Guardant Health from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Guggenheim restated a “buy” rating and issued a $56.00 price target on shares of Guardant Health in a research report on Monday, February 24th. Raymond James reaffirmed an “outperform” rating and issued a $59.00 price objective (up from $39.00) on shares of Guardant Health in a research note on Friday, February 21st. Stifel Nicolaus lifted their target price on shares of Guardant Health from $45.00 to $53.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Finally, Morgan Stanley upped their price target on shares of Guardant Health from $42.00 to $52.00 and gave the company an “overweight” rating in a research report on Thursday, March 6th. Twenty investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $49.00.

Guardant Health Stock Performance

GH stock opened at $43.71 on Wednesday. The company has a market capitalization of $5.39 billion, a P/E ratio of -12.28 and a beta of 1.45. The company has a fifty day moving average price of $43.57 and a 200-day moving average price of $35.69. Guardant Health has a 52-week low of $15.81 and a 52-week high of $50.89.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). The company had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. As a group, sell-side analysts forecast that Guardant Health will post -2.9 earnings per share for the current fiscal year.

Institutional Trading of Guardant Health

A number of hedge funds and other institutional investors have recently bought and sold shares of GH. R Squared Ltd bought a new position in shares of Guardant Health in the fourth quarter valued at $26,000. SBI Securities Co. Ltd. acquired a new stake in shares of Guardant Health in the 4th quarter worth about $43,000. Kimelman & Baird LLC bought a new position in Guardant Health in the 4th quarter valued at about $58,000. NewEdge Advisors LLC boosted its stake in Guardant Health by 13.5% during the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company’s stock valued at $59,000 after purchasing an additional 230 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Guardant Health during the 4th quarter worth approximately $61,000. Institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.